Physician profile
Muhammad Mir
NPI 1912168501
$1,031.26
in general payments reported to CMS, 2019-2025
19 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $61.56 · 2022: $46.43 · 2023: $208 · 2024: $228 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $181.01 | 2024-2025 | |
| Janssen Biotech, INC. | $115.08 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $114.13 | 2019-2024 | Farxiga |
| Amgen INC. | $110.98 | 2022-2025 | Tavneos, Uplizna |
| Electromed, INC. | $72.55 | 2023-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $69.00 | 2023-2025 | |
| Vifor Pharma, INC. | $56.37 | 2023 | Veltassa |
| Glaxosmithkline, LLC. | $41.38 | 2022-2024 | Jesduvroq |
| Paratek Pharmaceuticals, INC. | $38.49 | 2023 | Nuzyra |
| Shield Therapeutics INC | $32.90 | 2024 | |
| Merck Sharp & Dohme LLC | $32.74 | 2020-2023 | Verquvo |
| Travere Therapeutics, INC. | $29.82 | 2023 | |
| Mallinckrodt Enterprises LLC | $25.07 | 2019 | |
| Novo Nordisk INC | $24.29 | 2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $21.96 | 2025 | Purified Cortrophin Gel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $18.88 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.89 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $17.16 | 2019 | |
| Lilly USA, LLC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.